



AMENDMENTS TO THE CLAIMS


What is claimed is:

1. (Currently Amended) A compound of the formula



wherein

- (i) Q is a  radical in which R₃ is an alkoxy; Y is nitrogen; and R is a radical of the formula



wherein

R₄ is C₂₋₄alkyl, C₃₋₇cycloalkyl or C₅₋₇heterocycloalkyl;

R₅ and R₆ are independently hydrogen, halogen, cyano, R₇, -C(O)R₇ or -S(O)₂R₇ wherein

R₇ is -(CR₈R₉)_m-W-R₁₀ in which

R₈ and R₉ are independently hydrogen or lower alkyl;


W is a bond,


R₁₀ is hydrogen, alkyl, cycloalkyl, aryl or heterocyclyl;

m is zero or an integer from 1 to 5; and

n is zero or an integer of 1 or 2;

or an optical isomer thereof; or a pharmaceutically acceptable salt thereof; or

- (ii) Q is a  radical in which R₃ is alkoxy; and R is a radical of the formula



wherein

R_4 is C_{2-4} alkyl, C_{3-7} cycloalkyl or C_{5-7} heterocycloalkyl;

R_5 and R_6 are independently hydrogen, halogen, cyano, R_7 , $-C(O)R_7$ or $-S(O)_2R_7$ wherein

R_7 is $-(CR_8R_9)_m-W-R_{10}$ in which

R_8 and R_9 are independently hydrogen or lower alkyl;

W is a bond;

R_{10} is hydrogen, alkyl, cycloalkyl, aryl or heterocyclyl;


m is zero or an integer from 1 to 5; and

n is zero or an integer of 1 or 2;

or an optical isomer thereof; or a pharmaceutically acceptable salt thereof.

2 - 3. (Cancelled)

4. (Previously Presented) A compound according to Claim 1 of the formula



wherein

R_3 is alkoxy;

R_4 is C_{2-4} alkyl, C_{3-7} cycloalkyl or C_{5-7} heterocycloalkyl;

R_5 and R_6 are independently hydrogen, halogen, cyano, R_7 , $-C(O)R_7$ or $-S(O)_2R_7$ wherein

R_7 is $-(CR_8R_9)_m-W-R_{10}$ in which

R_8 and R_9 are, independently, hydrogen or lower alkyl;

W is a bond;

R_{10} is hydrogen, alkyl, cycloalkyl, aryl or heterocyclyl;

m is zero or an integer from 1 to 5;


Y is nitrogen;

n is zero or an integer of 1 or 2;

or an optical isomer thereof; or a pharmaceutically acceptable salt thereof.

5. (Original) A compound according to Claim 4, wherein
R₄ is cyclopentyl;
n is zero;
or an optical isomer thereof; or a pharmaceutically acceptable salt thereof.

6. (Previously Presented) A compound according to Claim 1 of the formula



wherein

- R₃ is alkoxy;
R₄ is C₂₋₄alkyl, C₃₋₇cycloalkyl or C₅₋₇heterocycloalkyl;
R₅ and R₆ are independently hydrogen, halogen, cyano, R₇, -C(O)R₇ or -S(O)₂R₇ wherein
R₇ is -(CR₈R₉)_m-W-R₁₀ in which
R₈ and R₉ are, independently, hydrogen or lower alkyl;
W is a bond;
R₁₀ is hydrogen, alkyl, cycloalkyl, aryl or heterocyclyl;
m is zero or an integer from 1 to 5;
n is zero or an integer of 1 or 2;
or an optical isomer thereof; or a pharmaceutically acceptable salt thereof.

7. (Original) A compound according to Claim 6, wherein
R₄ is cyclopentyl;
n is zero;
or an optical isomer thereof; or a pharmaceutically acceptable salt thereof.

8 – 11. (Cancelled)

12. (Withdrawn, Previously Presented) A method for the activation of glucokinase activity in mammals which method comprises administering to a mammal in need thereof a therapeutically

effective amount of a compound of claim 1, or an optical isomer thereof; or a pharmaceutically acceptable salt thereof.

13. (Withdrawn, Previously Presented) A method for the prevention and/or treatment of conditions associated with glucokinase activity in mammals which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1, or an optical isomer thereof; or a pharmaceutically acceptable salt thereof.

14. (Withdrawn, Previously Presented) The method according to claim 13, which method comprises administering said compound, or an optical isomer thereof; or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of insulin, insulin derived mimetic; insulin secretagogue; insulinotropic sulfonylurea receptor ligand; PPAR ligand; insulin sensitizer; biguanide; alpha-glucose inhibitors; GLP-1, GLP-1 analog or mimetic; DPPIV inhibitor; HMG-CoA reductase inhibitor; squaline synthase inhibitor; FXR or LXR ligand; cholestyramine; fibrates; nicotinic acid; or aspirin.


15. (Withdrawn, Previously Presented) A method for the treatment of impaired glucose tolerance, Type 2 diabetes and obesity which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1, or an optical isomer thereof; or a pharmaceutically acceptable salt thereof.

16. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claims 1, or an optical isomer thereof; or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable carriers.

17. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, or an optical isomer thereof; or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically effective amount of insulin, insulin derived mimetic; insulin secretagogue; insulinotropic sulfonylurea receptor ligand; PPAR ligand; insulin sensitizer; biguanide; alpha-glucose inhibitors; GLP-1, GLP-1 analog or mimetic; DPPIV inhibitor; HMG-CoA reductase inhibitor; squaline synthase inhibitor; FXR or LXR ligand; cholestyramine; fibrates; nicotinic acid; or aspirin.

18 – 24. (Cancelled)

25. (Previously Presented) A compound according to Claim 6, wherein the compound is:



or an optical isomer thereof; or a pharmaceutically acceptable salt thereof.